Site for COG AALL1731 A Phase 3 Trial Investigating Blinatumomab (IND# 117467 NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients wi

Brief description of study

Site for COG AALL1731, A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients wi


Clinical Study Identifier: s19-01032
ClinicalTrials.gov Identifier: NCT03914625


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.